HASBROUCK HEIGHTS, N.J., May 5, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today that NX02-0018, the second Phase 3 U.S. clinical trial for NX-1207, the Company's investigational drug for BPH, has begun screening and enrolment of patients. The protocol and patient materials for Trial NX02-0018 have been officially approved by the Investigational Review Board.
